SLC5A2 and chronic kidney disease: SGLT-2 inhibitors, through various physiological and metabolic mechanisms, not only significantly slow the progression of non-diabetic CKD but also improve fatigue and enhance physical endurance, thereby significantly improving patients’ overall quality of life.